AARTI DRUGS LIMITED
L37060MH1984PLC055433
DataDelta records 7 directors, 32 financial line items, 173 NSE events, and 4 group companies for AARTI DRUGS LIMITED. Appointment dates and ownership percentages are withheld until they pass a data-quality check.
- ISIN
- INE767A01016
- NSE
- AARTIDRUGS
- BSE
- 524348
- Listing
- Listed
- Status
- Active
- State
- maharashtra
- Class
- Public
- Industry
- Manufacturing (Others)
Events
50 shown of 173
| Date | Type | Status | Title |
|---|---|---|---|
| 2026-09-26 | ShareholderMeeting | Announced | Aarti Drugs Limited has informed the Exchange regarding 'Presentaion made to the shareholders at 41st AGM'. |
| 2026-09-26 | ShareholderMeeting | Announced | Aarti Drugs Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 26, 2026. Further, the company has informed the Exchange regarding voting results. |
| 2026-09-26 | BoardChange | Announced | Aarti Drugs Limited has informed the Exchange regarding Change in Director(s) of the company. |
| 2026-09-26 | ShareholderMeeting | Announced | Aarti Drugs Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 26, 2026 |
| 2026-09-02 | ShareholderMeeting | Completed | Aarti Drugs Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 26, 2026 |
| 2026-08-27 | BoardMeeting | Completed | Aarti Drugs Limited has informed the Exchange regarding Outcome of Board Meeting held on August 27, 2026. |
| 2026-08-24 | TradingWindow | Announced | Aarti Drugs Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 |
| 2026-08-24 | ESOP | Announced | AARTI DRUGS LIMITED has informed the Exchange about Board Meeting to be held on 27-Aug-2026 to consider ESOP. |
| 2026-08-24 | BoardMeeting | Completed | To consider 'Aarti Drugs Limited Performance Stock Option Plan 2026 , |
| 2026-08-10 | Disclosure | Announced | Aarti Drugs Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company |
| 2026-08-01 | Disclosure | Announced | Aarti Drugs Limited has informed the Exchange about Action(s) taken or orders passed |
| 2026-08-01 | Disclosure | Announced | Aarti Drugs Limited has informed the Exchange regarding a press release dated August 01, 2026, titled "Q1FY27 Business & Financial Performance". |
| 2026-07-31 | BoardMeeting | Completed | Aarti Drugs Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026. |
| 2026-07-31 | BoardMeeting | Completed | Aarti Drugs Limited has informed the Exchange regarding Outcome of Board Meeting held on July 31, 2026. |
| 2026-07-31 | Disclosure | Announced | Aarti Drugs Limited has informed the Exchange regarding a press release dated July 31, 2026, titled "Aarti Drugs Limited Announces Leadership Transition to Strengthen Governance and Ensure Long-Term Strategic Growth". |
| 2026-07-24 | BoardMeeting | Completed | AARTI DRUGS LIMITED has informed the Exchange about Board Meeting to be held on 31-Jul-2026 to inter-alia consider and approve the Audited Financial results of the Company for the Quarterly ended June 2026 . |
| 2026-07-24 | FinancialResults | Completed | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 2026-07-18 | Disclosure | Announced | Aarti Drugs Limited has informed the Exchange about Action(s) taken or orders passed |
| 2026-07-06 | Acquisition | Announced | Harshit M. Savla has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. |
| 2026-07-01 | Acquisition | Announced | Harshit M. Savla has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. |
| 2026-06-26 | TradingWindow | Announced | Aarti Drugs Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 |
| 2026-05-16 | Disclosure | Announced | Aarti Drugs Limited has informed the Exchange regarding a press release dated May 16, 2026, titled "Q4&FY26 Business and Financial Performance". |
| 2026-05-15 | Appointment | Announced | Aarti Drugs Limited has informed the Exchange about General Updates - Re-appointment of Cost Auditor and Internal Auditor |
| 2026-05-15 | BoardMeeting | Completed | Aarti Drugs Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026. |
| 2026-05-08 | FinancialResults | Completed | To consider and approve the financial results for the period ended March 31, 2026 |
| 2026-05-08 | BoardMeeting | Completed | AARTI DRUGS LIMITED has informed the Exchange about Board Meeting to be held on 15-May-2026 to inter-alia consider and approve the Audited Financial results of the Company for the Yearly ended March 2026 . |
| 2026-04-06 | Disclosure | Announced | Aarti Drugs Limited has informed the Exchange regarding a press release dated April 06, 2026, titled "Second 100 days Campaign". |
| 2026-03-25 | TradingWindow | Announced | Aarti Drugs Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 |
| 2026-03-24 | CreditRating | Announced | Aarti Drugs Limited has informed the Exchange about Credit Rating |
| 2026-03-16 | Disclosure | Announced | Aarti Drugs Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company |
| 2026-02-09 | Dividend | Completed | Interim Dividend - Rs 2 Per Share |
| 2026-02-03 | Dividend | Completed | Financial Results and Interim Dividend |
| 2026-02-03 | Dividend | Completed | Aarti Drugs Limited has informed the Exchange that Board of Directors at its meeting held on February 03, 2026, declared Interim Dividend of Rs. 2 per equity share. |
| 2026-02-03 | Dividend | Completed | Aarti Drugs Limited has informed the Exchange that Record date for the purpose of Dividend is 09-Feb-2026. |
| 2026-02-03 | Disclosure | Announced | Aarti Drugs Limited has informed the Exchange about change in Management |
| 2026-02-03 | Disclosure | Announced | Aarti Drugs Limited has informed the Exchange regarding a press release dated February 03, 2026, titled "Press Release on Q3& 9M FY26 financial ". |
| 2026-01-29 | CreditRating | Announced | Aarti Drugs Limited has informed the Exchange about Credit Rating |
| 2026-01-27 | Dividend | Completed | To consider and approve the financial results for the period ended December 31, 2025 and Interim dividend for FY 2025-26, if any |
| 2026-01-27 | Dividend | Completed | AARTI DRUGS LIMITED has informed the Exchange about Board Meeting to be held on 03-Feb-2026 to consider and approve the Quarterly Audited Financial results of the Company for the period ended December 2025 and Dividend. |
| 2025-12-29 | TradingWindow | Announced | Aarti Drugs Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 |
| 2025-11-07 | BoardMeeting | Completed | Aarti Drugs Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025. |
| 2025-11-07 | Disclosure | Announced | Aarti Drugs Limited has informed the Exchange regarding a press release dated 0 , , titled "Q2 & H1 FY26 Business & Financial Performance". |
| 2025-10-31 | FinancialResults | Completed | To consider and approve the financial results for the period ended September 30, 2025 |
| 2025-10-31 | BoardMeeting | Completed | AARTI DRUGS LIMITED has informed the Exchange about Board Meeting to be held on 07-Nov-2025 to inter-alia consider and approve the Audited Financial results of the Company for the Quarterly ended September 2025 . |
| 2025-10-06 | Disclosure | Announced | Aarti Drugs Limited has informed the Exchange about Action(s) taken or orders passed |
| 2025-09-29 | TradingWindow | Announced | Aarti Drugs Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 |
| 2025-09-24 | ShareholderMeeting | Completed | Aarti Drugs Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 24, 2025 |
| 2025-09-24 | ShareholderMeeting | Completed | Aarti Drugs Limited has informed the Exchange regarding 'Presentation made to the shareholders at 40th AGM'. |
| 2025-09-24 | ShareholderMeeting | Completed | Aarti Drugs Limited has informed the Exchange about re-appointment of Director and appointment of Secretarial Auditor at AGM |
| 2025-09-24 | ShareholderMeeting | Completed | Aarti Drugs Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 24, 2025. Further, the company has informed the Exchange regarding voting results. |
Directors
7 shown of 7
| Name | DIN | Designation | Status |
|---|---|---|---|
| Ajit E. Venugopalan | 09439069 | Independent Director | Active |
| Director and Shri Harit P. Shah | 00005501 | Managing Director | Active |
| Hasmukh B. Dedhia | 07510925 | Independent Director | Active |
| Re-appointment of Shri Ankit Vikram Paleja | 06975564 | Independent Director | Active |
| and Shri Sandeep M. Joshi | 00516409 | — | Active |
| term of Shri Prakash Moreshwar Patil | 00005618 | Whole-time Director | Active |
| terms of Shri Harshit M. Savla | 00005340 | Managing Director | Active |
Financials
32 shown of 32
| Year | Metric | Value | Unit |
|---|---|---|---|
| 2025-26 | CostOfMaterials | 1,50,401.39 | Lakhs |
| 2025-26 | CostOfMaterials | 1,40,184.71 | Lakhs |
| 2025-26 | Depreciation | 6,697.07 | Lakhs |
| 2025-26 | Depreciation | 5,564.03 | Lakhs |
| 2025-26 | EmployeeBenefits | 9,627.34 | Lakhs |
| 2025-26 | EmployeeBenefits | 12,931.7 | Lakhs |
| 2025-26 | OtherIncome | 259.35 | Lakhs |
| 2025-26 | OtherIncome | 238.92 | Lakhs |
| 2025-26 | Revenue | 2,26,038.5 | Lakhs |
| 2025-26 | Revenue | 2,56,531.12 | Lakhs |
| 2025-26 | Tax | 1,208.45 | Lakhs |
| 2025-26 | Tax | 1,596.41 | Lakhs |
| 2025-26 | TotalExpenses | 2,08,167.33 | Lakhs |
| 2025-26 | TotalExpenses | 2,35,679.86 | Lakhs |
| 2025-26 | TotalIncome | 2,56,770.04 | Lakhs |
| 2025-26 | TotalIncome | 2,26,297.85 | Lakhs |
| 2024-25 | CostOfMaterials | 1,35,387.55 | Lakhs |
| 2024-25 | CostOfMaterials | 1,43,384.2 | Lakhs |
| 2024-25 | Depreciation | 4,778.9 | Lakhs |
| 2024-25 | Depreciation | 5,577.68 | Lakhs |
| 2024-25 | EmployeeBenefits | 8,525.25 | Lakhs |
| 2024-25 | EmployeeBenefits | 11,209.84 | Lakhs |
| 2024-25 | OtherIncome | 1,357.1 | Lakhs |
| 2024-25 | OtherIncome | 1,636.04 | Lakhs |
| 2024-25 | Revenue | 2,38,703.03 | Lakhs |
| 2024-25 | Revenue | 2,17,365.49 | Lakhs |
| 2024-25 | Tax | 4,143.94 | Lakhs |
| 2024-25 | Tax | 4,367.44 | Lakhs |
| 2024-25 | TotalExpenses | 1,98,847.17 | Lakhs |
| 2024-25 | TotalExpenses | 2,19,161.93 | Lakhs |
| 2024-25 | TotalIncome | 2,40,339.07 | Lakhs |
| 2024-25 | TotalIncome | 2,18,722.59 | Lakhs |
Group companies
4 shown of 4
| Company | Relationship | Country |
|---|---|---|
| Limited and Aarti Speciality Chemicals Limited | Subsidiary | — |
| Pinnacle Life Science Private Limited | Subsidiary | — |
| Speciality Chemicals Limited | Subsidiary | — |
| Statutory Reports Aarti Drugs Limited | Subsidiary | — |